214 related articles for article (PubMed ID: 37753928)
1. Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease.
Sela M; Poley M; Mora-Raimundo P; Kagan S; Avital A; Kaduri M; Chen G; Adir O; Rozencweig A; Weiss Y; Sade O; Leichtmann-Bardoogo Y; Simchi L; Aga-Mizrachi S; Bell B; Yeretz-Peretz Y; Or AZ; Choudhary A; Rosh I; Cordeiro D; Cohen-Adiv S; Berdichevsky Y; Odeh A; Shklover J; Shainsky-Roitman J; Schroeder JE; Hershkovitz D; Hasson P; Ashkenazi A; Stern S; Laviv T; Ben-Zvi A; Avital A; Ashery U; Maoz BM; Schroeder A
Adv Mater; 2023 Dec; 35(51):e2304654. PubMed ID: 37753928
[TBL] [Abstract][Full Text] [Related]
2. Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson's Disease.
Kundu P; Das M; Tripathy K; Sahoo SK
ACS Chem Neurosci; 2016 Dec; 7(12):1658-1670. PubMed ID: 27642670
[TBL] [Abstract][Full Text] [Related]
3. Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson's disease mouse model.
Mobahat M; Sadroddiny E; Nooshabadi VT; Ebrahimi-Barough S; Goodarzi A; Malekshahi ZV; Ai J
Cell Tissue Bank; 2023 Mar; 24(1):75-91. PubMed ID: 35641803
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
[TBL] [Abstract][Full Text] [Related]
5. Gut-to-Brain α-Synuclein Transmission in Parkinson's Disease: Evidence for Prion-like Mechanisms.
Chen M; Mor DE
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108366
[TBL] [Abstract][Full Text] [Related]
6. Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease.
Guo M; Wang J; Zhao Y; Feng Y; Han S; Dong Q; Cui M; Tieu K
Brain; 2020 May; 143(5):1476-1497. PubMed ID: 32355963
[TBL] [Abstract][Full Text] [Related]
7. CSF-derived extracellular vesicles from patients with Parkinson's disease induce symptoms and pathology.
Herman S; Djaldetti R; Mollenhauer B; Offen D
Brain; 2023 Jan; 146(1):209-224. PubMed ID: 35881523
[TBL] [Abstract][Full Text] [Related]
8. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
9. Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy.
Zhang N; Yan F; Liang X; Wu M; Shen Y; Chen M; Xu Y; Zou G; Jiang P; Tang C; Zheng H; Dai Z
Theranostics; 2018; 8(8):2264-2277. PubMed ID: 29721078
[No Abstract] [Full Text] [Related]
10. Use of PEGylated Immunoliposomes to Deliver Dopamine Across the Blood-Brain Barrier in a Rat Model of Parkinson's Disease.
Kang YS; Jung HJ; Oh JS; Song DY
CNS Neurosci Ther; 2016 Oct; 22(10):817-23. PubMed ID: 27350533
[TBL] [Abstract][Full Text] [Related]
11. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
[TBL] [Abstract][Full Text] [Related]
12. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Lee S; Kim S; Park YJ; Yun SP; Kwon SH; Kim D; Kim DY; Shin JS; Cho DJ; Lee GY; Ju HS; Yun HJ; Park JH; Kim WR; Jung EA; Lee S; Ko HS
Hum Mol Genet; 2018 Jul; 27(13):2344-2356. PubMed ID: 29897434
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of the small molecule 03A10 as an inhibitor of α-synuclein aggregation for Parkinson's disease treatment.
Wang Q; Yao S; Yang ZX; Zhou C; Zhang Y; Zhang Y; Zhang L; Li JT; Xu ZJ; Zhu WL; Zhang NX; Ye Y; Feng LY
Acta Pharmacol Sin; 2023 Jun; 44(6):1122-1134. PubMed ID: 36627343
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
15. Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson's disease management.
Sola P; Krishnamurthy P; Chintamaneni PK; Pindiprolu SKSS; Kumari M
Expert Opin Drug Deliv; 2020 Aug; 17(8):1119-1132. PubMed ID: 32497457
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease.
Amo-Aparicio J; Daly J; Højen JF; Dinarello CA
J Neuroinflammation; 2023 Jun; 20(1):147. PubMed ID: 37349821
[TBL] [Abstract][Full Text] [Related]
17. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
18. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM; Gravel C; Lévesque M
J Parkinsons Dis; 2021; 11(1):71-92. PubMed ID: 33104039
[TBL] [Abstract][Full Text] [Related]
19. Immunoliposomes doubly targeted to transferrin receptor and to α-synuclein.
Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
Future Sci OA; 2015 Nov; 1(4):FSO71. PubMed ID: 28031922
[TBL] [Abstract][Full Text] [Related]
20. Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment.
Que R; Zheng J; Chang Z; Zhang W; Li H; Xie Z; Huang Z; Wang HT; Xu J; Jin D; Yang W; Tan EK; Wang Q
Front Immunol; 2021; 12():794770. PubMed ID: 34925379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
